Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

Abstract Background Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved CDK 4/6 inhibitor, and its combination with venetoclax, a BCL2 inhi...

Full description

Bibliographic Details
Main Authors: Diana Malarikova, Radek Jorda, Kristyna Kupcova, Jana Senavova, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Kristina Nozickova, Dana Sovilj, Celine Bellanger, David Chiron, Ladislav Andera, Vladimir Krystof, Miroslav Strnad, Karel Helman, Magdalena Klanova, Marek Trneny, Ondrej Havranek, Pavel Klener
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Experimental Hematology & Oncology
Subjects:
Cyclin-dependent kinase (CDK) inhibitors
Palbociclib
BCL2
Venetoclax
RB1
Mantle cell lymphoma (MCL)
Online Access:https://doi.org/10.1186/s40164-024-00499-2

Internet

https://doi.org/10.1186/s40164-024-00499-2

Similar Items